FDA Offers Technical Specs and Considerations for ANDAs

Drug Industry Daily
A A
The FDA issued guidance Wednesday recommending technical specifications and general considerations on how certain comparative clinical endpoint bioequivalence study data and skin adhesion and irritation/sensitization study data for ANDAs should be submitted using FDA-supported data standards.

To View This Article:

Login

Subscribe To Drug Industry Daily